University of South Florida

The United States Government As Represented by the Department of Veterans Affairs

Niketa A Patel

Denise Ratzlaff Cooper

Wayne Charles Guida

Robert Pleasants Sparks

Rekha S Patel

Jianfeng Cai

Paula Cole Bickford

Lisa Gould

Cesario V Borlongan

Kirpal Singh Bisht

Ghattas El Bassit

Mack Wu

Provided herein are exosomal compositions and exsosomal lncRNA compositions and formulations thereof. Also provided herein are methods of treating a wound in a subject in need thereof that can contain the step of administering an exosomal composition and/or exsosomal lncRNA compositions or formulation thereof to a wound in a subject in need thereof.

Adipose derived stem cell exosomes and uses thereof

Provided herein are formulations that can contain an effective amount of a PKCδ inhibitor. Also provided herein are methods of inhibiting a PKCδ in a subject in need thereof, that can include the step of administering an effective amount of a compound that is capable of inhibiting a PKCδ.

PKC-Delta-I inhibitor formulations and uses thereof

Provided herein are compounds that can bind GAS5 long non-coding RNA, compositions thereof, and uses thereof.

GAS5 binding compounds, formulations, and uses thereof

Described herein are assays, methods, and devices for diagnosing/prognosing Alzheimer's disease (AD) and/or a neurodegenerative disease in a subject. The assays, methods, and/or devices described herein can be configured to detect GAS5 long-coding RNAs and/or expression thereof in a sample from a subject.

Methods and compositions for diagnosis and management of neurodegerative diseases

Provided herein are formulations that can contain an effective amount of a PKC&#x3b4; inhibitor. Also provided herein are methods of inhibiting a PKC&#x3b4; in a subject in need thereof, that can include the step of administering an effective amount of a compound that is capable of inhibiting a PKC&#x3b4;.

PKC-delta-I inhibitor formulations and uses thereof

Brain injury can be caused by trauma or may occur in stroke or neurodegenerative diseases. The disclosure relates to compositions that can include exosomes isolated from human adipose-derived stem cells (hASC) and methods where exosomes from hASC may be used alone or in combination with insulin for the treatment of brain injury.

Exosomes from human adipose-derived stem cells for the treatment of brain injury

Various scaffolds of small molecules capable of binding to the active site of sortilin are identified by in silico methods. These scaffolds include norbornene anhydride amino acid adducts and 2-substituted 3-oxo-1,2,3,4-tetrahydro-2-quinoxalines. These sortilin ligands increase the uptake of glucose in 3T3L1 cells and can be employed in compositions to increase uptake of glucose for the treatment of diabetic patents.

Sortilin-binding small molecules for increasing glucose uptake

Described herein are assays, methods, and devices for diagnosing/prognosing diabetes, metabolic syndrome, pre-diabetic state and/or the early-onset of diabetes in a subject. The assays, methods, and devices described herein can be configured to detect one or more long-coding RNAs in a sample from a subject.

Methods and compositions for diagnosis and management of diabetes and metabolic syndrome

A method of reprogramming omental adipose cells to a subcutaneous-like lineage is presented herein. The method comprises exposing omental adipose cells to a small molecule such as Basic Fibroblast Growth Factor (bFGF); TRC105; long noncoding RNAs (lncRNAs) MALAT1, GAS5, linc-VLDLR; transcription factors Sox15, Oct4, KLF4, Nanog, Sal4, BMI1; or combinations thereof.

Method of characterizing and manipulating adipose stem cell depots to a metabolically healthy state

A method of treating traumatic brain injury (TBI) and other neurological disorders is presented herein. Both conditioned media (CM) containing long non-coding RNAs such as NEAT1 (nuclear enriched abundant transcript 1) and MALAT1 (metastasis associated lung adenocarcinoma transcript 1) as well as human adipose-derived stem cells (hADSCs) themselves (Tx), when administered at least 3 hours post injury, were found to significantly ameliorate motor and cognitive functions in young, but not aged, mice undergoing TBI. Significant reduction in cortical damage and hippocampal cell loss was observed in both Tx and CM groups in young rats, whereas less neuroprotection was detected in the aged rats and mainly in the Tx group but not the CM group, which may in part result from decreased homing of the cells to the spleen.

Method of treating neurological disorders using long non-coding RNAs

Modified stilbenoids and formulations thereof are provided. The modified stilbenoids can include one or more amino or amino-alkyl substituents. The formulation can be for the treatment or prevention of obesity and the modified stilbenoid present in an effective amount to alleviate or prevent the onset of one or more symptoms of obesity. Methods of making the modified stilbenoids and formulations thereof are provided. Methods are provided for treating a subject with a modified stilbenoid in an effective amount to alleviate or prevent one or more symptoms associated with diabetes, cardiovascular disease, high blood pressure, deep vein thrombosis, osteoarthritis, obstructive sleep apnea, cancer, and non-alcoholic fatty liver disease. The administration of the modified stilbenoids can result in decreased levels of PKC&#x3b4;II, PKC&#x3b4;VIII, substantially unaltered expression of PKC&#x3b4;I; a decreased number of adipocytes; increased weight and/or fat loss; or a combination thereof.

Compositions and methods for adipocyte modulation

The subject invention pertains to nucleic acid constructs for post-transcriptional control of expression of a polynucleotide encoding a protein in a cell, wherein the constructs include a metabolite responsive instability element such as the glucose-regulated mRNA instability element. The subject invention further pertains to host cells and vectors comprising the nucleic acid constructs of the invention, as well as probes, methods, and kits for detecting metabolite responsive instability elements or mutations thereof. The present invention further concerns a reporter vector useful for detecting intracellular glucose and glucose-analogs, host cells genetically modified with the reporter vector, and methods for detecting intracellular glucose. The present invention utilizes an element that regulates messenger RNA (mRNA) stability in response to a metabolite such as glucose or a glucose analog. This glucose-regulated mRNA instability element has been mapped to the protein kinase C &#x3b2;II (PKC&#x3b2;II) mRNA that was found to decrease in the presence of elevated glucose levels. When cloned into a reporter vector, the region of PKC&#x3b2;II containing the mRNA instability element imparts glucose-sensitive instability to the mRNA that is transcribed, thereby down-regulating the expression of the reporter gene when glucose is elevated. The reporter vector of the present invention may be introduced into host cells, allowing detection of intracellular glucose and glucose analogs within intact, living cells in real-time and, optionally, in a high-throughput format.

Compositions and methods for detecting intracellular glucose and analogs thereof

The subject invention pertains to nucleic acid constructs for post-transcriptional control of expression of a ploynucleotide encoding a protein in a eukaryotic cell, wherein the constructs include a metabolite responsive instability element such as the glucose-regulated mRNA instability element. The subject invention further pertains to host cells and vectors comprising the nucleic acid constructs of the invention, as well as probes, methods, and kits for detecting metabolite responsive instability elements or mutations thereof.

Growing community of inventors

Land O Lakes, FL, United States of America

Niketa A Patel